| Name | Title | Contact Details |
|---|
ParetoHealth is a healthcare benefits solutions provider focused on midsize employers with 50 to 1,000 employees. The company aims to reduce healthcare cost volatility and improve financial outcomes through innovative self-insurance models. It has established itself as the largest health benefits captive in the U.S., managing over $6.6 billion in healthcare spending and serving more than 3,000 employers, which collectively cover over 1 million lives. The company offers a range of services, including its Risk Shield program, which provides a shared-risk model for predictable costs and stop-loss protection against large claims. Its Savings Engine utilizes data analytics and clinical expertise to manage medical costs and improve pharmacy solutions through the ParetoHealth Pharmacy Consortium. By pooling employers into a single risk pool, ParetoHealth enhances negotiating leverage and risk stabilization, allowing midsize businesses access to cost-saving tools typically available to larger corporations.
Bostons Grammy-winning Handel and Haydn Society performs Baroque and Classical music with a freshness, a vitality, and a creativity that inspires all ages. H+H has been captivating audiences for over 200 consecutive seasons (the most of any performing arts organization in the United States), speaking to its singular success at converting new audiences to this extraordinary music, generation after generation.
We partner with you to identify, develop, and equip the leaders that will take your business further. Having worked with over 600 organizations from 30 nations around the world, we are trusted consultants to Fortune 50 companies and startups alike. We blend over 20 years of insight, honed while transforming parent company Barry-Wehmiller into a thriving $3.5B people-centric organization. Chapman & Co. partners with you by listening to your specific needs in order to deliver a tailored and holistic solution or off the shelf turnkey products for your organization. An organization isnt just a workplace, its where individuals spend the most of their daily life. We believe the greatest opportunity for good in this world lies within the organizations we interact with every day, and it begins with their leaders. To learn more about Chapman & Co. or how to partner with us, visit www.ccoleadership.com
The Volkswagen Group with its headquarters in Wolfsburg is one of the worlds leading automobile manufacturers and the largest carmaker in Europe. The Group is made up of ten brands from seven European countries: Volkswagen, Volkswagen Nutzfahrzeuge, ŠKODA, SEAT, CUPRA, Audi, Lamborghini, Bentley, Porsche and Ducati. Our group sells vehicles in 153 countries and operates 114 production plants worldwide. Each working day, around 675,000 employees worldwide produce cars, are involved in vehicle-related services or work in the other fields of business. Our goal is to make mobility sustainable for us and for future generations. Our promise: With electric drive, digital networking and autonomous driving, we make the automobile clean, quiet, intelligent and safe. At the same time, our core product becomes even more emotional and offers a completely new driving experience. It is also becoming part of the solution when it comes to climate and environmental protection. In this way, the car can continue to be a cornerstone of contemporary, individual and affordable mobility in the future. #Shapingmobility Imprint & Legal: http://vw.de/legal-notice DAT: http://vw.de/dat
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.